Advice
Following an abbreviated submission
mesalazine 1200mg gastro-resistant prolonged release tablet (Mezavant XL®) is accepted for use within NHS Scotland for the induction of clinical and endoscopic remission in patients with mild to moderate, active ulcerative colitis, and for maintenance of remission.
It may be used in cases where mesalazine is an appropriate choice of treatment and offers the possible advantage of once-daily administration.
Download detailed advice28KB (PDF)
Medicine details
- Medicine name:
- mesalazine 1200mg gastro-resistant prolonged release tablet (Mezavant XL)
- SMC ID:
- 445/08
- Indication:
- for the induction of clinical and endoscopic remission in patients with mild to moderate active ulcerative colitis, and for maintenance remission
- Pharmaceutical company
- Shire Pharmaceuticals
- BNF chapter
- Gastro-intestinal system
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 10 March 2008